Free Trial
→ 25X predicted for “Amazon Coin” – starting December 16th? (From True Market Insiders) (Ad)

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 14 of 15

Slide 14
Back to 13
Continue to 15
 
Back to 13
Continue to 15
 

Vaxcyte (NASDAQ:PCVX)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$147.50 (56.9% Upside)

About Vaxcyte

Vaxcyte logoVaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/6/2024Cantor FitzgeraldReiterated RatingOverweight
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$140.00 ➝ $140.00
9/10/2024MizuhoBoost Price TargetOutperform ➝ Outperform$113.00 ➝ $163.00
9/4/2024Bank of AmericaBoost Price TargetBuy ➝ Buy$101.00 ➝ $140.00
9/3/2024Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$108.00 ➝ $129.00
9/3/2024Leerink PartnersBoost Price TargetOutperform ➝ Outperform$106.00 ➝ $153.00
9/3/2024BTIG ResearchBoost Price TargetBuy ➝ Buy$98.00 ➝ $160.00
9/3/2024Needham & Company LLCBoost Price TargetBuy ➝ Buy$95.00 ➝ $140.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00 ➝ $95.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00 ➝ $95.00
Slide 14
Back to 13
Continue to 15
 

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

Register For The Webinar To Discover

More From MarketBeat
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...
Crypto Swap Profits | Sponsored
15 Healthcare Stocks that Analysts Love in a Post-Pandemic World
There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutica...
MarketBeat
Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...
Paradigm Press | Sponsored
7 Gene Editing Stocks Offering Transformational Change
Investors are talking about the impact that artificial intelligence (AI) can have on their portfolios. But the...
MarketBeat